Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
- Mechanism
- Curator reviewed
MAOIs act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. MAO-A preferentially deaminates serotonin, melatonin, epinephrine and norepinephrine. MAO-B preferentially deaminates phenylethylamine and trace amines. Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Catecholamines cause general physiological changes that prepare the body for physical activity (fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system.
- Primary indication
- For the treatment of moderate to severe hypertension.Curator reviewed
- Formula / weight
- C11H13N · 159.2276 g/mol (avg)
- Code names
- A 19120 · Lopac-P-8013 · MO 911
Resolves to
DPWPWRLQFGFJFI-UHFFFAOYSA-NSMILESCN(CC#C)CC1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Pargyline, and which of those have an active Phase 3 trial?